Initial experience with an eight-month sustained-release intravitreal ganciclovir implant for the treatment of CMV retinitis associated with AIDS.


BACKGROUND AND OBJECTIVE An intravitreal device administering ganciclovir in a sustained-release fashion has been developed for site-specific therapy of cytomegalovirus (CMV) retinitis. The initially tested devices released ganciclovir at a rate of approximately 2 micrograms/hour (Mark I device), yielding an estimated in vivo therapeutic life span of 4… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics